Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you live on the Isle of Man and are researching weight loss injections, the short answer is this: Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines, legally available only following a clinical assessment by a qualified prescriber. A GPhC-registered online pharmacy can post treatment directly to an Isle of Man address once a prescriber has reviewed and approved your consultation. Access does not require a referral or a local clinic appointment. These medicines are not suitable for everyone, and a prescriber makes the final decision based on your individual health picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes. Mounjaro and Wegovy are licensed in the UK for weight management in adults, and there is no restriction that prevents someone on the Isle of Man from receiving a private prescription through a GPhC-registered online pharmacy. The Isle of Man is not part of the NHS in England, Wales or Scotland, so NHS commissioning routes (which are phased and criteria-heavy anyway) do not directly apply. Private prescribing through a regulated UK pharmacy is the practical route for most Isle of Man residents.
The process is straightforward. You complete a medical consultation online; a GPhC-registered Independent Prescriber reviews your answers and medical history; if treatment is clinically appropriate, your prescription is issued and your medication is dispensed from a UK pharmacy and sent out tracked. Delivery to the Isle of Man takes a little longer than a mainland next-working-day service, so it is worth asking your provider about expected transit times when you start. At nume, our clinical team reviews consultations the same day they are submitted, a named prescriber reads your answers, not an automated system.
One thing residents often ask about is whether a local GP needs to be involved. It is good clinical practice for your prescribing pharmacy to notify your GP, and this is in line with GPhC guidance, but you do not need a GP referral to begin a consultation. You can read more about what the consultation process involves, including which weight loss injection may be suitable for you, on our treatment page.
This is genuinely a question for your prescriber, because the right choice depends on your health history, any medicines you already take, and whether you have conditions that might make one option more suitable than the other. That said, understanding the difference helps you go into that conversation prepared.
Mounjaro (tirzepatide) is the only dual-agonist licensed for weight management in the UK. It activates both the GIP and GLP-1 hormone pathways, which together reduce appetite and slow the rate at which food leaves your stomach. Treatment starts at 2.5mg (a dose whose job is to let your body adjust, not to deliver the full therapeutic effect) and is titrated upward by your prescriber, typically in four-weekly steps, up to a maximum of 15mg. In SURMOUNT-1, involving 2,539 adults with obesity, average weight reduction at the 15mg dose reached around 20–21% over 72 weeks, as published in the New England Journal of Medicine.
Wegovy (semaglutide) works through the GLP-1 pathway alone. It follows a similar escalation schedule and has a strong evidence base of its own, the STEP 1 trial reported around 15% average weight loss over 68 weeks at the 2.4mg maintenance dose. A higher 7.2mg dose was approved by the MHRA in early 2026, with a dedicated single-dose pen approved on 14 April 2026. For a fuller comparison of how the two medicines differ, our page on types of weight loss injection covers the evidence side by side.
Both medicines are licensed for adults with a BMI of 30 or above, or a BMI of 27 or above if you have at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or osteoarthritis. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure on its own never decides suitability, the prescriber looks at your full health picture, including any medicines that could interact and conditions that would make these treatments unsuitable.
On side effects: the profile for both medicines is led by gastrointestinal symptoms. Nausea, loose stools, constipation and indigestion are the most commonly reported, particularly in the early weeks or after a dose increase, and they tend to settle as your body adapts. Most people find starting on a low dose reduces how noticeable these effects are. There are rarer but more serious symptoms to be aware of, pancreatitis is one. The MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: if you develop severe, persistent stomach pain that radiates to your back, seek urgent medical attention. You can report any suspected side effects, and flag any concerns about where your medicine came from, through the MHRA's Yellow Card scheme.
If you are using oral contraceptives and starting tirzepatide, add a non-oral method of contraception for the first four weeks of treatment and for four weeks after any dose increase, the absorption of the pill may be affected. If you are pregnant, trying to conceive, or breastfeeding, these medicines are not recommended. Our page on the drawbacks of weight loss injections covers these considerations in more detail so you can weigh them up honestly before starting.
This matters more than it might seem. Fake weight loss pens have been seized in large quantities by the MHRA, and some have been found to contain insulin rather than the medicine on the label. The MHRA has warned publicly about counterfeit pens sold via social media and websites offering these medicines without a clinical assessment, that absence of clinical review is one of the clearest red flags. Discount codes attached to prescription medicines from unverified sellers are another warning sign worth taking seriously.
The straightforward way to check any online pharmacy is the GPhC register. Every legitimate online pharmacy must be registered, and you can verify ours directly at the GPhC register (premises number 9012878). If a pharmacy is not listed, do not order from it. It is also worth reading about what "cheap" really means when it comes to prescription medicines, because a lower price from an unverified source is not a saving.
If you have questions before you start, our FAQs cover the things people most commonly ask, or you can get in touch with our team directly. When you are ready to take the next step, if you are weighing up 3 weight loss injections or want to explore all the options available, you can also browse our full range of weight loss injections before you check your eligibility and start your free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.